BGV’s Daniela Couto and Gina Melcher von Dydiowa together with Sander van Deventer of Forbion published an article in Nature Biotechnology on pharma involvement in biotech startup success. Click on this link to read the whole article. Abstract: Many novel...
Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience Successful serial entrepreneur with track record of growing companies, notably for Themis and Glycovaxyn Joins at a key juncture in Scenic Biotech’s strategic growth,...
Munich, Germany, January 28, 2021 — CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry...
Leiden, The Netherlands, 27 January 2021 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO). As CMO, Dr....
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeksOnce-daily oral icosabutate showed dose-dependent,...
BGV now one of the largest biotech investors in early stage ventures and company creation in Europe BGV IV includes new investors Eli Lilly and Company and Novo Holdings, joining existing investors Bristol Myers Squibb, European Investment Fund, Industriens Pension,...
